Actively Recruiting
CV CARE: CardioVascular Care in PC Patients
Led by Dana-Farber Cancer Institute · Updated on 2025-08-11
180
Participants Needed
2
Research Sites
154 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
N
National Comprehensive Cancer Network
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants. The name of the intervention used in this research study is: CV Care (cardiovascular risk assessment and management program)
CONDITIONS
Official Title
CV CARE: CardioVascular Care in PC Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have a histologic diagnosis of prostate adenocarcinoma at any stage with a treatment plan for at least 24 weeks of androgen deprivation therapy (ADT).
- Participants can have received up to 12 weeks of ADT therapy.
- Willingness to participate in two CV CARE visits at weeks 12 and 24 after starting ADT.
- Willingness to have follow-up visits for ADT management at Dana-Farber Cancer Institute Longwood site.
- Willingness to undergo lab and blood pressure assessments, including local labs or home blood pressure checks for virtual visits.
- Participants with pre-existing cardiovascular disease or risk factors are eligible but not required.
- Participants receiving combination treatment with androgen receptor signaling inhibitors, immunotherapy, or PARP inhibitors are eligible.
- Age 18 years or older.
- Life expectancy greater than 6 months.
- Ability to understand and willingness to sign informed consent.
You will not qualify if you...
- History of major adverse cardiac events such as myocardial infarction, new or worsening congestive heart failure, or stroke within the past 24 weeks requiring close cardiologist collaboration.
- Participants on ADT therapy for more than 12 weeks are ineligible.
- Participants receiving combination treatment with ADT and chemotherapy, radioligand therapy, or participating in other clinical trials are excluded.
- Active participation in therapeutic clinical trials is not allowed due to time constraints.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
Actively Recruiting
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
A
Alicia Morgans, MD, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here